CellWell record HH-344072
Targeting Lipoprotein(a): A New Era in Cardiovascular Disease Prevention
Yakubu Bene-Alhasan; Vijay Nambi; Layla A Abushamat; Christie M Ballantyne
2026
In plain language
Elevated lipoprotein(a) is an independent causal risk factor for atherosclerotic cardiovascular disease, and emerging therapies achieve up to 99% Lp(a) reductions in ongoing phase 3 trials.
- Evidence
- Emerging
- Design
- Expert review
Cite this record: https://thecellwell.org/studies/HH-344072
Produced by the CellWell Research Engine, custom software owned and operated by CellWell and The Holistic Hub. All rights reserved. This analysis, its indexing and its evidence classifications are proprietary. Any use, republication or onward sharing must credit CellWell Research Engine (thecellwell.org) as the source.
This is an educational research library, not medical advice. Nothing here may be used to diagnose, treat, cure, or prevent any disease. Always consult a qualified professional.